Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:17 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Mechanisms of EPO-induced Hypertension
NCT03810911 · VA Office of Research and Development · PHASE2 · terminated · last registry update 2025-12-15 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The trial was stopped because of inability to reach target sample size.” | – | Registry record, VA Office of Research and Development |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against EPOR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-29Results posted on the registry: Northwestern University, Erythropoietin (NCT05325073)
- 2026-10-23Results posted on the registry: The First Affiliated Hospital of Soochow University, Decitabine + Granulocyte Colony-Stimulating Factor (NCT05907499)
- 2026-08-04Also stopped (terminated): GlaxoSmithKline, GSK1278863 + Placebo (NCT02075463)
- 2026-07-23Results posted on the registry: University of Iowa, Epoetin Alpha (NCT02075970)
- 2026-06-09Phase 3 first posted: Nanfang Hospital, Southern Medical University, Luspatercept + Epoetin (NCT07636486)
- 2026-05-04Phase 3 first posted: Geoff Block, Epoetin alga (Epogen)/vadadustat (NCT07565701)
- 2026-03-12Results posted on the registry: Central Jutland Regional Hospital, a drug against EPOR (NCT06053138)
- 2026-02-20Phase 3 first posted: Takeda, Elritercept + Epoetin Alfa (NCT07422480)
- 2026-01-07Results posted on the registry: Julia Xu, Hydroxyurea + Epoetin Alfa-BioSimilar (NCT05451940)
- 2025-12-23Phase 3 first posted: Qilu Pharmaceutical Co., Ltd., Daprodustat + Darbepoetin alfa (NCT07300111)
- 2025-12-22Phase 3 first posted: Badr University, Erythropoietin + Probiotic + EPO (NCT07296146)
- 2025-09-12Phase 3 first posted: Fundacion Clinic per a la Recerca Biomédica, Darbepoetin (DP) (NCT07169643)
- 2025-08-13Phase 3 first posted: Biocad, BCD-131 (pegdarbepoetin beta) + Mircera (methoxypolyethylene glycol-epoetin beta) (NCT07119372)
- 2025-06-17Phase 3 first posted: Incepta Pharmaceuticals Ltd, Erythropoietin alfa (NCT07025681)
- 2025-05-22Results posted on the registry: Akebia Therapeutics, Vadadustat + Darbepoetin alfa (NCT04313153)
- 2025-04-18Results posted on the registry: United States Army Research Institute of Environmental Medicine, Epoetin Alfa (NCT05078138)
- 2025-04-06Results posted on the registry: Mayo Clinic, Iron Dextran + Erythropoietin (EPO) (NCT05167734)
- 2025-03-20Results posted on the registry: Bio Sidus SA, Erythropoietin alfa (NCT04036253)
- 2025-01-22Results posted on the registry: National Cancer Institute (NCI), Ibrutinib + Steroid pulse (prednisone) (NCT04294641)
- 2025-01-15Results posted on the registry: Akebia Therapeutics, Vadadustat + Mircera® (NCT04707768)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision